Evidence map›Paper›PMID 25888368›Full record

ArticleJournal of hematology & oncology2015

Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis.

Wei Wang, Guilin Tang, Jorge E Cortes, Hui Liu, Di Ai, C Cameron Yin, Shaoying Li, Joseph D Khoury, Carlos Bueso-Ramos, L Jeffrey Medeiros and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of hematology & oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 34 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. [The significance of non-Ph chromosome in chronic myelogenous leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Wei WangDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. wwang13@mdanderson.org.
Guilin TangDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. gtang@mdanderson.org.
Jorge E CortesDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. jcortes@mdanderson.org.
Hui LiuDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. HLiu8@mdanderson.org.
Di AiDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. aidium@hotmail.com.
C Cameron YinDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. cyin@mdanderson.org.
Shaoying LiDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. sli6@mdanderson.org.
Joseph D KhouryDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. jkhoury@mdanderson.org.
Carlos Bueso-RamosDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. cbuesora@mdanderson.org.
L Jeffrey MedeirosDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. ljmedeiros@mdanderson.org.
Shimin HuDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. shu1@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
6 · The paper itself

Abstract

backgroundProgression of chronic myelogenous leukemia (CML) is frequently accompanied by cytogenetic evolution, commonly unbalanced chromosomal changes, such as an extra copy of Philadelphia chromosome (Ph), +8, and i(17)(q10). Balanced chromosomal translocations typically found in de novo acute myeloid leukemia occur occasionally in CML, such as inv(3)/t(3;3), t(8;21), t(15;17), and inv(16). Translocations involving the 11q23, a relatively common genetic abnormality in acute leukemia, have been seldom reported in CML. In this study, we explored the prevalence and prognostic role of 11q23 in CML.

methodsWe searched our pathology archives for CML cases diagnosed in our institution from 1998 to present. Cases with 11q23 rearrangements were retrieved. The corresponding clinicopathological data were reviewed.

resultsA total of 2,012 cases of CML with available karyotypes were identified. Ten (0.5%) CML cases had 11q23 rearrangement in Ph-positive cells, including 4 cases of t(9;11), 2 cases of t(11;19), and 1 case each of t(2;11), t(4;11), t(6;11), and t(4;9;11). Eight cases (80%) had other concurrent chromosomal abnormalities. There were 6 men and 4 women with a median age of 50 years (range, 21-70 years) at time of initial diagnosis of CML. 11q23 rearrangement occurred after a median period of 12.5 months (range, 0-172 months): 1 patient in chronic phase, 2 in accelerated phase, and 7 in blast phase. Eight of ten patients died after a median follow-up of 16.5 months (range, 8-186 months) following the initial diagnosis of CML, and a median of 6.7 months (range, 0.8-16.6 months) after the emergence of 11q23 rearrangement. The remaining two patients had complete remission at the last follow-up, 50.2 and 6.9 months, respectively. In addition, we also identified a case with 11q23/t(11;17) in Ph-negative cells in a patient with a history of CML. MLL involvement was tested by fluorescence in situ hybridization in 10 cases, and 7 cases (70%) were positive.

conclusionsIn summary, chromosomal rearrangements involving 11q23 are rare in CML, frequently occurring in blast phase, and are often associated with other cytogenetic abnormalities. These patients had a low response rate to tyrosine kinase inhibitors and a poor prognosis.

Indexed as

AdultAgedBlast CrisisChromosomes, Human, Pair 11Disease ProgressionFemaleHumansKaryotypingLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedPrognosisTranslocation, GeneticYoung Adult

Identifiers

PMID25888368
PMCPMC4396174
OpenAlexW2151305042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.